Porcine Vaccine Market Size by Technology, Disease Indication, End User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2029
4.88%
CAGR (2023-2029)
2.66 USD Bn.
Market Size
308
Report Pages
156
Market Tables
Overview
Porcine Vaccine Market is expected to grow at a CAGR of 4.88% during the forecast period. Global Porcine Vaccine Market is expected to reach US$ 3.72 Bn. by 2029.
Government initiatives for encouraging animal farming combined with immense demand for pork and bacon are touted to drive the demand for vaccines. A large number of hog farms because of the export of pig end products to Asia and other regions can bolster the market size. The high per capita meat consumption by countries in the EU can facilitate the growth of the porcine vaccines market globally.
To know about the Research Methodology :- Request Free Sample Report
But high storage cost of these vaccines may hinder the market growth. The scope of the report includes a detailed study of global and regional markets for Global porcine vaccine market with the reasons given for variations in the growth of the industry in certain regions.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The report on the global porcine vaccine market covers segments such as technology, disease indication, and end-user industries. Based on end-user, the hog/pig production farm segment accounted for a leading share of the global porcine vaccines market in 2022 and is expected to gain market share by 2029. Growth of specialized pig production units in major countries worldwide and growing demand for pork meat and byproducts such as gelatin have led to prominent share by the hog production farms segment in the porcine vaccines market globally.
North America is expected to witness the fastest growth during the forecast period because of the subsequent rise of pig farming and growing cases of swine diseases. Rise in pig cultivation and contract farming in the U.S is deemed to trigger the market demand by 2029. Expansion of production facilities in the U.S, owing to the rising export of pig products for consumption can positively impact the regional market growth.
Europe holds the second-largest position in the porcine vaccination market and is expected to retain its positioning in the upcoming years of the forecast period. The growth of the market is attributed to the increasing number of production units for swine and a high consumption rate of pork meat.
The report also gives a key development in the market for porcine vaccines such as in April 2021, MSD Animal Health made an announced about the launch of its new and innovative triple-action sow care vaccine to fight against leptospirosis, porcine parvoviruses, and erysipelas. This one of a kind immunity vaccine against three dangerous diseases is a massive development in the industry.
Some commercially existing (non-autogenous) porcine reproductive and respiratory syndrome (PRRS) vaccines are:
Current Name Type Virus Strain Origin Manufacturer
Amervac-PRRS Attenuated European Hipra Laboratorios
Suvaxyn-PRRS2 Inactivated European Fort Dodge Veterinaria SA
Ingelvac PRRS ATP Attenuated North American Boehringer Ingelheim
PRRomiSe Inactivated North American Intervet
The objective of the report is to present comprehensive analysis of Global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding Global Porcine Vaccine Market dynamics, structure by analyzing the market segments, and project the Global market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Porcine Vaccine Market make the report investor’s guide.
Scope of the Global Porcine Vaccine Market: Inquire before buying
| Global Porcine Vaccine Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 2.66 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 4.88% | Market Size in 2029: | US $ 3.72 Bn. |
| Segments Covered: | by Technology | Inactivated Vaccines Live Attenuated Vaccines Toxoid Vaccines Recombinant Vaccines Conjugate Vaccines DNA Vaccines |
|
| by Disease Indication | Diarrhea Swine Influenza Arthritis Bordatella Rhinitis Porcine Reproductive and Respiratory Virus (PRRSV) Porcine Circovirus Associated Disease (PCVAD) Others |
||
| by End User | Veterinary Hospitals Hog/Pig Production Farm |
||
Porcine Vaccine Market, By Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Porcine Vaccine Market Key Players are:
1. Bayer AG.
2. Bimeda Animal Health
3. Boehringer Ingelheim GmbH
4. Ceva Sante Animale
5. Eli Lilly
6. Merck & Co., Inc.
7. Merial (Sanofi)
8. Vetoquinol
9. Zoetis, Inc.
10. Sanofi S.A.
11. PBS Animal Health,
12. Aptimmune
13. Formosa Biomedical INC
14. MVP
15. Shoken Pharmaceutical Co., Ltd
16. FATRO SpA
17. MSD Animal Health
18. HIPRA
19. Novartis AG
Frequently Asked questions
1. What is the market size of the Global Porcine Vaccine Market in 2022?
Ans. The market size Global Porcine Vaccine Market in 2022 was US$ 2.66 Billion.
2. What are the different segments of the Global Porcine Vaccine Market?
Ans. The Global Porcine Vaccine Market is divided into Technology , Disease Indication and End User.
3. What is the study period of this market?
Ans. The Global Porcine Vaccine Market will be studied from 2022 to 2029.
4. Which region is expected to hold the highest Global Porcine Vaccine Market share?
Ans. The Asia Pacific dominates the market share in the market.
5. What is the Forecast Period of Global Porcine Vaccine Market?
Ans. The Forecast Period of the market is 2023-2029 in the market.
Table of Contents
Global Porcine Vaccine Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Porcine Vaccine Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Porcine Vaccine Market Analysis and Forecast
6.1. Global Porcine Vaccine Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Porcine Vaccine Market Analysis and Forecast, By End User
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Porcine Vaccine Market Value Share Analysis, By End User
7.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By End User
7.5. Global Porcine Vaccine Market Analysis, By End User
7.6. Global Porcine Vaccine Market Attractiveness Analysis, By End User
8. Global Porcine Vaccine Market Analysis and Forecast, By Technology
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Porcine Vaccine Market Value Share Analysis, By Technology
8.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By Technology
8.5. Global Porcine Vaccine Market Analysis, By Technology
8.6. Global Porcine Vaccine Market Attractiveness Analysis, By Technology
9. Global Porcine Vaccine Market Analysis and Forecast, By Disease Indication
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Porcine Vaccine Market Value Share Analysis, By Disease Indication
9.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By Disease Indication
9.5. Global Porcine Vaccine Market Analysis, By Disease Indication
9.6. Global Porcine Vaccine Market Attractiveness Analysis, By Disease Indication
10. Global Porcine Vaccine Market Analysis, by Region
10.1. Global Porcine Vaccine Market Value Share Analysis, by Region
10.2. Global Porcine Vaccine Market Size (US$ Bn) Forecast, by Region
10.3. Global Porcine Vaccine Market Attractiveness Analysis, by Region
11. North America Porcine Vaccine Market Analysis
11.1. Key Findings
11.2. North America Porcine Vaccine Market Overview
11.3. North America Porcine Vaccine Market Value Share Analysis, By End User
11.4. North America Porcine Vaccine Market Forecast, By End User
11.4.1. Veterinary Hospitals
11.4.2. Hog/Pig Production Farm
11.5. North America Porcine Vaccine Market Value Share Analysis, By Technology
11.6. North America Porcine Vaccine Market Forecast, By Technology
11.6.1. Inactivated Vaccines
11.6.2. Live Attenuated Vaccines
11.6.3. Toxoid Vaccines
11.6.4. Recombinant Vaccines
11.6.5. Conjugate Vaccines
11.6.6. DNA Vaccines
11.7. North America Porcine Vaccine Market Value Share Analysis, By Disease Indication
11.8. North America Porcine Vaccine Market Forecast, By Disease Indication
11.8.1. Diarrhea
11.8.2. Swine Influenza
11.8.3. Arthritis
11.8.4. Bordatella Rhinitis
11.8.5. Porcine Reproductive and Respiratory Virus (PRRSV)
11.8.6. Porcine Circovirus Associated Disease (PCVAD)
11.8.7. Others.
11.9. North America Porcine Vaccine Market Value Share Analysis, by Country
11.10. North America Porcine Vaccine Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Porcine Vaccine Market Analysis, by Country
11.12. U.S. Porcine Vaccine Market Forecast, By End User
11.12.1. Veterinary Hospitals
11.12.2. Hog/Pig Production Farm
11.13. U.S. Porcine Vaccine Market Forecast, By Technology
11.13.1. Inactivated Vaccines
11.13.2. Live Attenuated Vaccines
11.13.3. Toxoid Vaccines
11.13.4. Recombinant Vaccines
11.13.5. Conjugate Vaccines
11.13.6. DNA Vaccines
11.14. U.S. Porcine Vaccine Market Forecast, By Disease Indication
11.14.1. Diarrhea
11.14.2. Swine Influenza
11.14.3. Arthritis
11.14.4. Bordatella Rhinitis
11.14.5. Porcine Reproductive and Respiratory Virus (PRRSV)
11.14.6. Porcine Circovirus Associated Disease (PCVAD)
11.14.7. Others.
11.15. Canada Porcine Vaccine Market Forecast, By End User
11.15.1. Veterinary Hospitals
11.15.2. Hog/Pig Production Farm
11.16. Steel Canada Porcine Vaccine Market Forecast, By Technology
11.16.1. Inactivated Vaccines
11.16.2. Live Attenuated Vaccines
11.16.3. Toxoid Vaccines
11.16.4. Recombinant Vaccines
11.16.5. Conjugate Vaccines
11.16.6. DNA Vaccines
11.17. Canada Porcine Vaccine Market Forecast, By Disease Indication
11.17.1. Diarrhea
11.17.2. Swine Influenza
11.17.3. Arthritis
11.17.4. Bordatella Rhinitis
11.17.5. Porcine Reproductive and Respiratory Virus (PRRSV)
11.17.6. Porcine Circovirus Associated Disease (PCVAD)
11.17.7. Others.
11.18. North America Porcine Vaccine Market Attractiveness Analysis
11.18.1. By End User
11.18.2. By Technology
11.18.3. By Disease Indication
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Porcine Vaccine Market Analysis
12.1. Key Findings
12.2. Europe Porcine Vaccine Market Overview
12.3. Europe Porcine Vaccine Market Value Share Analysis, By End User
12.4. Europe Porcine Vaccine Market Forecast, By End User
12.4.1. Veterinary Hospitals
12.4.2. Hog/Pig Production Farm
12.5. Europe Porcine Vaccine Market Value Share Analysis, By Technology
12.6. Europe Porcine Vaccine Market Forecast, By Technology
12.6.1. Inactivated Vaccines
12.6.2. Live Attenuated Vaccines
12.6.3. Toxoid Vaccines
12.6.4. Recombinant Vaccines
12.6.5. Conjugate Vaccines
12.6.6. DNA Vaccines
12.7. Europe Porcine Vaccine Market Value Share Analysis, By Disease Indication
12.8. Europe Porcine Vaccine Market Forecast, By Disease Indication
12.8.1. Diarrhea
12.8.2. Swine Influenza
12.8.3. Arthritis
12.8.4. Bordatella Rhinitis
12.8.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.8.6. Porcine Circovirus Associated Disease (PCVAD)
12.8.7. Others.
12.9. Europe Porcine Vaccine Market Value Share Analysis, by Country
12.10. Europe Porcine Vaccine Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Porcine Vaccine Market Analysis, by Country
12.12. Germany Porcine Vaccine Market Forecast, By End User
12.12.1. Veterinary Hospitals
12.12.2. Hog/Pig Production Farm
12.13. Germany Porcine Vaccine Market Forecast, By Technology
12.13.1. Inactivated Vaccines
12.13.2. Live Attenuated Vaccines
12.13.3. Toxoid Vaccines
12.13.4. Recombinant Vaccines
12.13.5. Conjugate Vaccines
12.13.6. DNA Vaccines
12.14. Germany Porcine Vaccine Market Forecast, By Disease Indication
12.14.1. Diarrhea
12.14.2. Swine Influenza
12.14.3. Arthritis
12.14.4. Bordatella Rhinitis
12.14.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.14.6. Porcine Circovirus Associated Disease (PCVAD)
12.14.7. Others.
12.15. U.K. Porcine Vaccine Market Forecast, By End User
12.15.1. Veterinary Hospitals
12.15.2. Hog/Pig Production Farm
12.16. U.K. Porcine Vaccine Market Forecast, By Technology
12.16.1. Inactivated Vaccines
12.16.2. Live Attenuated Vaccines
12.16.3. Toxoid Vaccines
12.16.4. Recombinant Vaccines
12.16.5. Conjugate Vaccines
12.16.6. DNA Vaccines
12.17. U.K. Porcine Vaccine Market Forecast, By Disease Indication
12.17.1. Diarrhea
12.17.2. Swine Influenza
12.17.3. Arthritis
12.17.4. Bordatella Rhinitis
12.17.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.17.6. Porcine Circovirus Associated Disease (PCVAD)
12.17.7. Others.
12.18. France Porcine Vaccine Market Forecast, By End User
12.18.1. Veterinary Hospitals
12.18.2. Hog/Pig Production Farm
12.19. France Porcine Vaccine Market Forecast, By Technology
12.19.1. Inactivated Vaccines
12.19.2. Live Attenuated Vaccines
12.19.3. Toxoid Vaccines
12.19.4. Recombinant Vaccines
12.19.5. Conjugate Vaccines
12.19.6. DNA Vaccines
12.20. France Porcine Vaccine Market Forecast, By Disease Indication
12.20.1. Diarrhea
12.20.2. Swine Influenza
12.20.3. Arthritis
12.20.4. Bordatella Rhinitis
12.20.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.20.6. Porcine Circovirus Associated Disease (PCVAD)
12.20.7. Others.
12.21. Italy Porcine Vaccine Market Forecast, By End User
12.21.1. Veterinary Hospitals
12.21.2. Hog/Pig Production Farm
12.22. Italy Porcine Vaccine Market Forecast, By Technology
12.22.1. Inactivated Vaccines
12.22.2. Live Attenuated Vaccines
12.22.3. Toxoid Vaccines
12.22.4. Recombinant Vaccines
12.22.5. Conjugate Vaccines
12.22.6. DNA Vaccines
12.23. Italy Porcine Vaccine Market Forecast, By Disease Indication
12.23.1. Diarrhea
12.23.2. Swine Influenza
12.23.3. Arthritis
12.23.4. Bordatella Rhinitis
12.23.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.23.6. Porcine Circovirus Associated Disease (PCVAD)
12.23.7. Others.
12.24. Spain Porcine Vaccine Market Forecast, By End User
12.24.1. Veterinary Hospitals
12.24.2. Hog/Pig Production Farm
12.25. Spain Porcine Vaccine Market Forecast, By Technology
12.25.1. Inactivated Vaccines
12.25.2. Live Attenuated Vaccines
12.25.3. Toxoid Vaccines
12.25.4. Recombinant Vaccines
12.25.5. Conjugate Vaccines
12.25.6. DNA Vaccines
12.26. Spain Porcine Vaccine Market Forecast, By Disease Indication
12.26.1. Diarrhea
12.26.2. Swine Influenza
12.26.3. Arthritis
12.26.4. Bordatella Rhinitis
12.26.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.26.6. Porcine Circovirus Associated Disease (PCVAD)
12.26.7. Others.
12.27. Rest of Europe Porcine Vaccine Market Forecast, By End User
12.27.1. Veterinary Hospitals
12.27.2. Hog/Pig Production Farm
12.28. Rest of Europe Porcine Vaccine Market Forecast, By Technology
12.28.1. Inactivated Vaccines
12.28.2. Live Attenuated Vaccines
12.28.3. Toxoid Vaccines
12.28.4. Recombinant Vaccines
12.28.5. Conjugate Vaccines
12.28.6. DNA Vaccines
12.29. Rest Of Europe Porcine Vaccine Market Forecast, By Disease Indication
12.29.1. Diarrhea
12.29.2. Swine Influenza
12.29.3. Arthritis
12.29.4. Bordatella Rhinitis
12.29.5. Porcine Reproductive and Respiratory Virus (PRRSV)
12.29.6. Porcine Circovirus Associated Disease (PCVAD)
12.29.7. Others.
12.30. Europe Porcine Vaccine Market Attractiveness Analysis
12.30.1. By End User
12.30.2. By Technology
12.30.3. By Disease Indication
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Porcine Vaccine Market Analysis
13.1. Key Findings
13.2. Asia Pacific Porcine Vaccine Market Overview
13.3. Asia Pacific Porcine Vaccine Market Value Share Analysis, By End User
13.4. Asia Pacific Porcine Vaccine Market Forecast, By End User
13.4.1. Veterinary Hospitals
13.4.2. Hog/Pig Production Farm
13.5. Asia Pacific Porcine Vaccine Market Value Share Analysis, By Technology
13.6. Asia Pacific Porcine Vaccine Market Forecast, By Technology
13.6.1. Inactivated Vaccines
13.6.2. Live Attenuated Vaccines
13.6.3. Toxoid Vaccines
13.6.4. Recombinant Vaccines
13.6.5. Conjugate Vaccines
13.6.6. DNA Vaccines
13.7. Asia Pacific Porcine Vaccine Market Value Share Analysis, By Disease Indication
13.8. Asia Pacific Porcine Vaccine Market Forecast, By Disease Indication
13.8.1. Diarrhea
13.8.2. Swine Influenza
13.8.3. Arthritis
13.8.4. Bordatella Rhinitis
13.8.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.8.6. Porcine Circovirus Associated Disease (PCVAD)
13.8.7. Others.
13.9. Asia Pacific Porcine Vaccine Market Value Share Analysis, by Country
13.10. Asia Pacific Porcine Vaccine Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Porcine Vaccine Market Analysis, by Country
13.12. China Porcine Vaccine Market Forecast, By End User
13.12.1. Veterinary Hospitals
13.12.2. Hog/Pig Production Farm
13.13. China Porcine Vaccine Market Forecast, By Technology
13.13.1. Inactivated Vaccines
13.13.2. Live Attenuated Vaccines
13.13.3. Toxoid Vaccines
13.13.4. Recombinant Vaccines
13.13.5. Conjugate Vaccines
13.13.6. DNA Vaccines
13.14. China Porcine Vaccine Market Forecast, By Disease Indication
13.14.1. Diarrhea
13.14.2. Swine Influenza
13.14.3. Arthritis
13.14.4. Bordatella Rhinitis
13.14.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.14.6. Porcine Circovirus Associated Disease (PCVAD)
13.14.7. Others.
13.15. India Porcine Vaccine Market Forecast, By End User
13.15.1. Veterinary Hospitals
13.15.2. Hog/Pig Production Farm
13.16. India Porcine Vaccine Market Forecast, By Technology
13.16.1. Inactivated Vaccines
13.16.2. Live Attenuated Vaccines
13.16.3. Toxoid Vaccines
13.16.4. Recombinant Vaccines
13.16.5. Conjugate Vaccines
13.16.6. DNA Vaccines
13.17. India Porcine Vaccine Market Forecast, By Disease Indication
13.17.1. Diarrhea
13.17.2. Swine Influenza
13.17.3. Arthritis
13.17.4. Bordatella Rhinitis
13.17.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.17.6. Porcine Circovirus Associated Disease (PCVAD)
13.17.7. Others.
13.18. Japan Porcine Vaccine Market Forecast, By End User
13.18.1. Veterinary Hospitals
13.18.2. Hog/Pig Production Farm
13.19. Japan Porcine Vaccine Market Forecast, By Technology
13.19.1. Inactivated Vaccines
13.19.2. Live Attenuated Vaccines
13.19.3. Toxoid Vaccines
13.19.4. Recombinant Vaccines
13.19.5. Conjugate Vaccines
13.19.6. DNA Vaccines
13.20. Japan Porcine Vaccine Market Forecast, By Disease Indication
13.20.1. Diarrhea
13.20.2. Swine Influenza
13.20.3. Arthritis
13.20.4. Bordatella Rhinitis
13.20.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.20.6. Porcine Circovirus Associated Disease (PCVAD)
13.20.7. Others.
13.21. ASEAN Porcine Vaccine Market Forecast, By End User
13.21.1. Veterinary Hospitals
13.21.2. Hog/Pig Production Farm
13.22. ASEAN Porcine Vaccine Market Forecast, By Technology
13.22.1. Inactivated Vaccines
13.22.2. Live Attenuated Vaccines
13.22.3. Toxoid Vaccines
13.22.4. Recombinant Vaccines
13.22.5. Conjugate Vaccines
13.22.6. DNA Vaccines
13.23. ASEAN Porcine Vaccine Market Forecast, By Disease Indication
13.23.1. Diarrhea
13.23.2. Swine Influenza
13.23.3. Arthritis
13.23.4. Bordatella Rhinitis
13.23.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.23.6. Porcine Circovirus Associated Disease (PCVAD)
13.23.7. Others.
13.24. Rest of Asia Pacific Porcine Vaccine Market Forecast, By End User
13.24.1. Veterinary Hospitals
13.24.2. Hog/Pig Production Farm
13.25. Rest of Asia Pacific Porcine Vaccine Market Forecast, By Technology
13.25.1. Inactivated Vaccines
13.25.2. Live Attenuated Vaccines
13.25.3. Toxoid Vaccines
13.25.4. Recombinant Vaccines
13.25.5. Conjugate Vaccines
13.25.6. DNA Vaccines
13.26. Rest of Asia Pacific Porcine Vaccine Market Forecast, By Disease Indication
13.26.1. Diarrhea
13.26.2. Swine Influenza
13.26.3. Arthritis
13.26.4. Bordatella Rhinitis
13.26.5. Porcine Reproductive and Respiratory Virus (PRRSV)
13.26.6. Porcine Circovirus Associated Disease (PCVAD)
13.26.7. Others.
13.27. Asia Pacific Porcine Vaccine Market Attractiveness Analysis
13.27.1. By End User
13.27.2. By Technology
13.27.3. By Disease Indication
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Porcine Vaccine Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Porcine Vaccine Market Overview
14.3. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By End User
14.4. Middle East & Africa Porcine Vaccine Market Forecast, By End User
14.4.1. Veterinary Hospitals
14.4.2. Hog/Pig Production Farm
14.5. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By Technology
14.6. Middle East & Africa Porcine Vaccine Market Forecast, By Technology
14.6.1. Inactivated Vaccines
14.6.2. Live Attenuated Vaccines
14.6.3. Toxoid Vaccines
14.6.4. Recombinant Vaccines
14.6.5. Conjugate Vaccines
14.6.6. DNA Vaccines
14.7. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By Disease Indication
14.8. Middle East & Africa Porcine Vaccine Market Forecast, By Disease Indication
14.8.1. Diarrhea
14.8.2. Swine Influenza
14.8.3. Arthritis
14.8.4. Bordatella Rhinitis
14.8.5. Porcine Reproductive and Respiratory Virus (PRRSV)
14.8.6. Porcine Circovirus Associated Disease (PCVAD)
14.8.7. Others.
14.9. Middle East & Africa Porcine Vaccine Market Value Share Analysis, by Country
14.10. Middle East & Africa Porcine Vaccine Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Porcine Vaccine Market Analysis, by Country
14.12. GCC Porcine Vaccine Market Forecast, By End User
14.12.1. Veterinary Hospitals
14.12.2. Hog/Pig Production Farm
14.13. GCC Porcine Vaccine Market Forecast, By Technology
14.13.1. Inactivated Vaccines
14.13.2. Live Attenuated Vaccines
14.13.3. Toxoid Vaccines
14.13.4. Recombinant Vaccines
14.13.5. Conjugate Vaccines
14.13.6. DNA Vaccines
14.14. GCC Porcine Vaccine Market Forecast, By Disease Indication
14.14.1. Diarrhea
14.14.2. Swine Influenza
14.14.3. Arthritis
14.14.4. Bordatella Rhinitis
14.14.5. Porcine Reproductive and Respiratory Virus (PRRSV)
14.14.6. Porcine Circovirus Associated Disease (PCVAD)
14.14.7. Others.
14.15. South Africa Porcine Vaccine Market Forecast, By End User
14.15.1. Veterinary Hospitals
14.15.2. Hog/Pig Production Farm
14.16. South Africa Porcine Vaccine Market Forecast, By Technology
14.16.1. Inactivated Vaccines
14.16.2. Live Attenuated Vaccines
14.16.3. Toxoid Vaccines
14.16.4. Recombinant Vaccines
14.16.5. Conjugate Vaccines
14.16.6. DNA Vaccines
14.17. South Africa Porcine Vaccine Market Forecast, By Disease Indication
14.17.1. Diarrhea
14.17.2. Swine Influenza
14.17.3. Arthritis
14.17.4. Bordatella Rhinitis
14.17.5. Porcine Reproductive and Respiratory Virus (PRRSV)
14.17.6. Porcine Circovirus Associated Disease (PCVAD)
14.17.7. Others.
14.18. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By End User
14.18.1. Veterinary Hospitals
14.18.2. Hog/Pig Production Farm
14.19. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By Technology
14.19.1. Inactivated Vaccines
14.19.2. Live Attenuated Vaccines
14.19.3. Toxoid Vaccines
14.19.4. Recombinant Vaccines
14.19.5. Conjugate Vaccines
14.19.6. DNA Vaccines
14.20. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By Disease Indication
14.20.1. Diarrhea
14.20.2. Swine Influenza
14.20.3. Arthritis
14.20.4. Bordatella Rhinitis
14.20.5. Porcine Reproductive and Respiratory Virus (PRRSV)
14.20.6. Porcine Circovirus Associated Disease (PCVAD)
14.20.7. Others.
14.21. Middle East & Africa Porcine Vaccine Market Attractiveness Analysis
14.21.1. By End User
14.21.2. By Technology
14.21.3. By Disease Indication
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments
15. South America Porcine Vaccine Market Analysis
15.1. Key Findings
15.2. South America Porcine Vaccine Market Overview
15.3. South America Porcine Vaccine Market Value Share Analysis, By End User
15.4. South America Porcine Vaccine Market Forecast, By End User
15.4.1. Veterinary Hospitals
15.4.2. Hog/Pig Production Farm
15.5. South America Porcine Vaccine Market Value Share Analysis, By Technology
15.6. South America Porcine Vaccine Market Forecast, By Technology
15.6.1. Inactivated Vaccines
15.6.2. Live Attenuated Vaccines
15.6.3. Toxoid Vaccines
15.6.4. Recombinant Vaccines
15.6.5. Conjugate Vaccines
15.6.6. DNA Vaccines
15.7. South America Porcine Vaccine Market Value Share Analysis, By Disease Indication
15.8. South America Porcine Vaccine Market Forecast, By Disease Indication
15.8.1. Diarrhea
15.8.2. Swine Influenza
15.8.3. Arthritis
15.8.4. Bordatella Rhinitis
15.8.5. Porcine Reproductive and Respiratory Virus (PRRSV)
15.8.6. Porcine Circovirus Associated Disease (PCVAD)
15.8.7. Others.
15.9. South America Porcine Vaccine Market Value Share Analysis, by Country
15.10. South America Porcine Vaccine Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Porcine Vaccine Market Analysis, by Country
15.12. Brazil Porcine Vaccine Market Forecast, By End User
15.12.1. Veterinary Hospitals
15.12.2. Hog/Pig Production Farm
15.13. Brazil Porcine Vaccine Market Forecast, By Technology
15.13.1. Inactivated Vaccines
15.13.2. Live Attenuated Vaccines
15.13.3. Toxoid Vaccines
15.13.4. Recombinant Vaccines
15.13.5. Conjugate Vaccines
15.13.6. DNA Vaccines
15.14. Brazil Porcine Vaccine Market Forecast, By Disease Indication
15.14.1. Diarrhea
15.14.2. Swine Influenza
15.14.3. Arthritis
15.14.4. Bordatella Rhinitis
15.14.5. Porcine Reproductive and Respiratory Virus (PRRSV)
15.14.6. Porcine Circovirus Associated Disease (PCVAD)
15.14.7. Others.
15.15. Mexico Porcine Vaccine Market Forecast, By End User
15.15.1. Veterinary Hospitals
15.15.2. Hog/Pig Production Farm
15.16. Mexico Porcine Vaccine Market Forecast, By Technology
15.16.1. Inactivated Vaccines
15.16.2. Live Attenuated Vaccines
15.16.3. Toxoid Vaccines
15.16.4. Recombinant Vaccines
15.16.5. Conjugate Vaccines
15.16.6. DNA Vaccines
15.17. Mexico Porcine Vaccine Market Forecast, By Disease Indication
15.17.1. Diarrhea
15.17.2. Swine Influenza
15.17.3. Arthritis
15.17.4. Bordatella Rhinitis
15.17.5. Porcine Reproductive and Respiratory Virus (PRRSV)
15.17.6. Porcine Circovirus Associated Disease (PCVAD)
15.17.7. Others.
15.18. Rest of South America Porcine Vaccine Market Forecast, By End User
15.18.1. Veterinary Hospitals
15.18.2. Hog/Pig Production Farm
15.19. Rest of South America Porcine Vaccine Market Forecast, By Technology
15.19.1. Inactivated Vaccines
15.19.2. Live Attenuated Vaccines
15.19.3. Toxoid Vaccines
15.19.4. Recombinant Vaccines
15.19.5. Conjugate Vaccines
15.19.6. DNA Vaccines
15.20. Rest of South America Porcine Vaccine Market Forecast, By Disease Indication
15.20.1. Diarrhea
15.20.2. Swine Influenza
15.20.3. Arthritis
15.20.4. Bordatella Rhinitis
15.20.5. Porcine Reproductive and Respiratory Virus (PRRSV)
15.20.6. Porcine Circovirus Associated Disease (PCVAD)
15.20.7. Others.
15.21. South America Porcine Vaccine Market Attractiveness Analysis
15.21.1. By End User
15.21.2. By Technology
15.21.3. By Disease Indication
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Bayer AG.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. Bimeda Animal Health
16.3.3. Boehringer Ingelheim GmbH
16.3.4. Ceva Sante Animale
16.3.5. Eli Lilly
16.3.6. Merck & Co., Inc.
16.3.7. Merial (Sanofi)
16.3.8. Vetoquinol
16.3.9. Zoetis, Inc.
16.3.10. Sanofi S.A.
16.3.11. PBS Animal Health,
16.3.12. Aptimmune
16.3.13. Formosa Biomedical INC
16.3.14. MVP
16.3.15. Shoken Pharmaceutical Co., Ltd
16.3.16. FATRO SpA
16.3.17. MSD Animal Health
16.3.18. HIPRA
16.3.19. Novartis AG
17. Primary Key Insights